Arrowhead Pharmaceuticals has acquired an FDA Rare Pediatric Disease Priority Review Voucher to accelerate the review of its Supplemental New Drug Application (SNDA) for plozasiran for severe hypertriglyceridemia (sHTG). This move aims to shorten the FDA's review period from 10 months to 6 months, potentially bringing the drug to market faster for a broader patient population.
Arrowhead Pharmaceuticals (ARWR) has announced the acquisition of a Priority Review Voucher (PRV) for its upcoming SNDA submission for plozasiran, targeting severe hypertriglyceridemia (sHTG). This is a significant development because a PRV accelerates the FDA review process from 10 months to 6 months, potentially allowing ARWR to commercialize plozasiran for this expanded indication much sooner. The company's confidence is bolstered by positive Phase 3 results, and sHTG represents a larger market opportunity than its current approved indication (FCS). This short-term acceleration could lead to earlier revenue generation and market penetration, offering a positive catalyst for ARWR stock, as it de-risks the timeline for a key pipeline asset.